grant
Targeting non-genetic and genetic mechanisms to overcome drug resistance in acute myeloid leukemia
NIHUS FederalResearch GrantFY20261.beta.-D-ArabinofuranosylcytosineAML - Acute Myeloid LeukemiaARA-cellAcute Myeloblastic LeukemiaAcute Myelocytic LeukemiaAcute Myelogenous LeukemiaAddressAlexanApoptosisApoptosis PathwayApoptoticArabineArabinofuranosylcytosineArabinosylcytosineAracytidineAracytinAracytineAssayAutomobile DrivingB-Cell Chronic Lymphocytic Leukemia Associated OncogeneB-cell Leukemia 1BCLBCL1 OncogeneBar CodesBioassayBiologic ModelsBiological AssayBiological ModelsCRISPRCRISPR/Cas systemCancer CenterCancersCell BodyCell Communication and SignalingCell DeathCell SignalingCellsChemicalsChromatinCitrullusClonal EvolutionClustered Regularly Interspaced Short Palindromic RepeatsCollaborationsCytarabineCytarabinumCytarbelCytosarCytosar-UCytosarUCytosine ArabinosideCytosine-.beta.-arabinosideCytotoxic ChemotherapyCytotoxic TherapyDNADNA mutationDeoxyribonucleic AcidDependenceDetectable Residual DiseaseDevelopmentDiagnosisDiseaseDisease remissionDisorderDisparateDrug TargetingDrug TherapyDrug ToleranceDrug resistanceDrug usageDrugsEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessErpalfaEvolutionFluorescenceFunctional dependenceGene TranscriptionGeneticGenetic ChangeGenetic DiversityGenetic TranscriptionGenetic VariationGenetic defectGenetic mutationGenotypeHematopoietic Cell TumorHematopoietic MalignanciesHematopoietic NeoplasmsHematopoietic Neoplasms including LymphomasHematopoietic TumorHematopoietic and Lymphoid Cell NeoplasmHematopoietic and Lymphoid NeoplasmsHistonesIntracellular Communication and SignalingIntratumoral heterogeneityKnock-outKnockoutLabelLibrariesMCL-1MCL1MCL1 geneMalignant CellMalignant Hematopoietic NeoplasmMalignant NeoplasmsMalignant TumorMeasurementMeasuresMediatingMedicationMemoryMinimal Residual DiseaseMitochondriaModel SystemModelingMolecularMulti-Drug ResistanceMultidrug ResistanceMultiple Drug ResistanceMultiple Drug ResistantMutationMyelogenousMyeloidPDX modelPathway interactionsPatient derived xenograftPatientsPatternPharmaceutical PreparationsPharmacological TreatmentPharmacotherapyPhasePhenotypePreparednessPrimary NeoplasmPrimary TumorProgrammed Cell DeathRNA ExpressionReadinessRelapseRemissionReportingResidual NeoplasmResidual TumorsResistanceResistance developmentResistance to Multi-drugResistance to MultidrugResistance to Multiple DrugResistant developmentResistant to Multiple DrugResistant to multi-drugResistant to multidrugRestRetrospective cohortSamplingSignal TransductionSignal Transduction SystemsSignalingSortingSystemTarabine PFSTestingTherapeuticTranscriptionUdicilWatermelonacute granulocytic leukemiaacute myeloid leukemiabarcodebiological signal transductionblood cancercancer cellcancer of bloodcancer of the bloodchemotherapycohortdetermine efficacydeveloping resistancedevelopmentaldrivingdrug efficacydrug interventiondrug resistantdrug sensitivitydrug treatmentdrug usedrug/agenteffective therapyeffective treatmentefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationentire genomeepigeneticallyevaluate efficacyexamine efficacyfull genomegenetic architecturegenetic evolutiongenome mutationgenome scalegenome-widegenomewideheterogeneity in tumorsin vivoin vivo Modelindexinginhibitorinnovateinnovationinnovativeintra-tumoral heterogeneityintratumor heterogeneityleukemialeukemia relapseleukemia treatmentleukemic therapymalignancymitochondrialmulti-drug resistantmultidrug resistantmultiomicsmultiple omicsmutational statusmyeloblastmyeloid cell leukemia 1myeloid cell leukemia sequence 1myeloid leukemia cell differentiation proteinnecrocytosisneoplasm/cancernew drug targetnew druggable targetnew pharmacotherapy targetnew therapeutic targetnew therapy targetnon-geneticnongeneticnovelnovel drug targetnovel druggable targetnovel pharmacotherapy targetnovel therapeutic targetnovel therapy targetpanomicspathwaypatient derived xenograft modelpatient responsepatient specific responsepharmaceutical interventionpharmacological interventionpharmacological therapypharmacology interventionpharmacology treatmentpharmacotherapeuticsphenotypic dataprecision medicineprecision-based medicinepreventpreventingprogramsprospectiverecurrent leukemiaresidual diseaseresistance to Drugresistance to therapyresistantresistant to Drugresistant to therapyresponseresponsive patientspecific biomarkersstandard of caresuccesstargeted agenttargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic resistancetherapy resistanttranscriptomicstreatment resistancetumor heterogeneitywhole genome
Description preview
PROJECT SUMMARY
Most patients diagnosed with acute myeloid leukemia (AML) die of the disease due to development of
resistance to existing chemotherapy or targeted therapy. This problem underscores the compelling
need for understanding of relapse emergence mechanisms and identification of effective targeted
strategies to overcome leukemia relapse.…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click